How have ATBPD shares performed in 2024?

Antibe Therapeutics' stock was trading at $0.6820 on January 1st, 2024. Since then, ATBPD stock has decreased by 68.4% and is now trading at $0.2156. View the best growth stocks for 2024 here .

How do I buy shares of Antibe Therapeutics?

Shares of ATBPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:ATBPD

Antibe Therapeutics (ATBPD) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free ATBPD Stock Alerts

$0.22

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.22
▼
$0.22
50-Day Range: $0.12
▼
$0.78
52-Week Range: $2.64
▼
$3.50

Volume: N/A
Average Volume: 29,710 shs
Market Capitalization: $83.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart

Get Antibe Therapeutics alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Antibe Therapeutics Stock (OTCMKTS:ATBPD)

Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

ATBPD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATBPD Stock News Headlines

April 1, 2024 | marketwatch.com

Antibe Therapeutics Shares Down on Clinical Hold on Otenaproxesul by U.S. Regulator

April 1, 2024 | marketwatch.com

Antibe Therapeutics Drug Otenaproxesul Placed on Clinical Hold by FDA

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

June 29, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Antibe Therapeutics (OtherATBPF), Terns Pharmaceuticals (TERN) and Aquestive Therapeutics (AQST)

See More Headlines

Receive ATBPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:ATBPD
CUSIP: N/A
CIK: N/A
Web: www.antibethera.com
Phone: 416 922 3460
Fax: N/A
Employees: 47
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,540,000.00
Net Margins: -273.96%
Pretax Margin: N/A
Return on Equity: -150.49%
Return on Assets: -98.51%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.97
Quick Ratio: 5.42

Sales & Book Value

Annual Sales: $7.51 million
Price / Sales: 11.11
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.10 per share
Price / Book: 2.16

Miscellaneous

Outstanding Shares: 387,000,000
Free Float: N/A
Market Cap: $83.44 million
Optionable: Not Optionable
Beta: 0.57

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Daniel Marcel Legault (Age 62)
Pres, CEO, Sec. & Director
Dr. John Lawrence Wallace M.B.A. (Age 63)
M.Sc., MSc, Ph.D., MBA, Founder, Chief Scientific Officer & Director
Mr. Alain Wilson M.B.A.
MBA, Chief Financial Officer
Dr. David James Vaughan (Age 70)
Chief Devel. Officer
Mr. Scott Curtis C.F.A.
M.Eng, CFA, Exec. VP
Ms. Christina Cameron B.B.A.
VP of Investor Relations
Mr. Philip Stern
VP of Communications
Dr. Rami Batal M.B.A.
Ph.D., Chief Commercial Officer
Ms. Ella Korets Smith M.B.A.
M.Sc., Head of Regional Bus. Devel.
Dr. Joseph Stauffer (Age 54)
Chief Medical Officer

Key Competitors

View All Competitors

ATBPD Stock Analysis - Frequently Asked Questions

How have ATBPD shares performed in 2024?: Antibe Therapeutics' stock was trading at $0.6820 on January 1st, 2024. Since then, ATBPD stock has decreased by 68.4% and is now trading at $0.2156.
View the best growth stocks for 2024 here.
How do I buy shares of Antibe Therapeutics?: Shares of ATBPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ATBPD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial